XOMA Corp (XOMA)
23.90
-0.62
(-2.53%)
USD |
NASDAQ |
Jun 26, 10:38
XOMA SG&A Expense (TTM): 27.87M for March 31, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 27.87M |
December 31, 2023 | 25.61M |
September 30, 2023 | 25.91M |
June 30, 2023 | 24.34M |
March 31, 2023 | 24.27M |
December 31, 2022 | 23.19M |
September 30, 2022 | 21.16M |
June 30, 2022 | 20.62M |
March 31, 2022 | 18.84M |
December 31, 2021 | 20.46M |
September 30, 2021 | 18.60M |
June 30, 2021 | 17.55M |
March 31, 2021 | 17.18M |
December 31, 2020 | 16.80M |
September 30, 2020 | 17.42M |
June 30, 2020 | 20.03M |
March 31, 2020 | 21.42M |
December 31, 2019 | 21.00M |
September 30, 2019 | 21.04M |
June 30, 2019 | 19.87M |
March 31, 2019 | 19.33M |
December 31, 2018 | 18.56M |
September 30, 2018 | 20.95M |
June 30, 2018 | 23.55M |
March 31, 2018 | 24.34M |
Date | Value |
---|---|
December 31, 2017 | 24.34M |
September 30, 2017 | 22.81M |
June 30, 2017 | 19.61M |
March 31, 2017 | 19.18M |
December 31, 2016 | 18.32M |
September 30, 2016 | 17.84M |
June 30, 2016 | 19.42M |
March 31, 2016 | 19.70M |
December 31, 2015 | 20.62M |
September 30, 2015 | 20.01M |
June 30, 2015 | 19.73M |
March 31, 2015 | 19.83M |
December 31, 2014 | 19.87M |
September 30, 2014 | 20.82M |
June 30, 2014 | 20.69M |
March 31, 2014 | 19.61M |
December 31, 2013 | 18.48M |
September 30, 2013 | 17.38M |
June 30, 2013 | 16.82M |
March 31, 2013 | 16.31M |
December 31, 2012 | 16.86M |
September 30, 2012 | 18.15M |
June 30, 2012 | 20.78M |
March 31, 2012 | 23.32M |
December 31, 2011 | 24.01M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
16.80M
Minimum
Dec 2020
27.87M
Maximum
Mar 2024
21.16M
Average
20.81M
Median
SG&A Expense (TTM) Benchmarks
Viracta Therapeutics Inc | 16.64M |
AbbVie Inc | 13.15B |
AnaptysBio Inc | 43.47M |
Cue Biopharma Inc | 16.69M |
NovaBay Pharmaceuticals Inc | 12.53M |